Navigation Links
Roche, Baylor Research Institute Partner in Human Immunology Research
Date:12/3/2010

DALLAS, Dec. 3, 2010 /PRNewswire-USNewswire/ -- Baylor Research Institute (BRI), the research arm of Baylor Health Care System, announced that it has formed a three-year partnership with Roche (SIX: RO, ROG; OTCQX: RHHBY) to jointly develop programs emerging from the human immunology platforms developed at the Baylor Institute for Immunology Research (BIIR), a component of BRI.

These programs will leverage BIIR's leading position in human immunology with particular focus on cancer vaccines, auto-immune disease diagnostics and treatment, proprietary platforms in biosignature and antibody development, with a view at identifying new leads that could be in-licensed by Roche. A Joint Research Committee will determine the most promising projects in that context, to be funded by Roche over a three-year period.

BRI will retain sole responsibility for programs outside the jointly developed projects.

"The worldwide reputation in human immunology established by Jacques Banchereau  and his team over the years and the uniqueness of some of their programs clearly fit Roche's strategic discovery plans for novel approaches in diagnosing and treating diseases where our company wants to expand its franchise," said Jean-Jacques Garaud, MD., Head of Roche Pharma Research & Early Development (pRED).

Banchereau, formerly the director at BIIR, is senior vice president, head of the Inflammation and Virology Discovery and Translational Areas and chief scientific officer at Roche.

"The partnership with a world leader such as Roche will help tremendously in accelerating the translation of our leading innovative science in human immunology, into diagnostics and treatments that will benefit patients worldwide," said Michael A.E. Ramsay, MD., FRCA, president of BRI.

About BRI: Established in 1984 in Dallas, Texas, Baylor Research Institute (BRI) promotes and supports research to bring innovative treatments from the laboratory workbench to the patient bedside. To achieve this bench-to-bedside concept, BRI focuses on basic science, clinical trials, healthcare effectiveness and quality of care research. Today, BRI is conducting more than 800 active research protocols with 250 research investigators, spanning more than 20 medical specialties, and has research and development projects in areas ranging from human immunology and orphan metabolic diseases to diabetes, cardio-vascular disease and many other unmet medical needs.

www.baylorhealth.edu/Research/FOR MORE INFORMATION, CONTACT: Kristine Hughes Communications Coordinator 214-820-7556 (O) kristine.hughes@baylorhealth.edu
'/>"/>

SOURCE BAYLOR RESEARCH INSTITUTE
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ambry Genetics Announces the Addition of Array CGH Services Through Partnership With Baylor College of Medicine
2. Leading LASIK Laser Eye Cataract Surgery Experts of Baylor Vision in Houston Join Trusted LASIK Surgeons Directory
3. NIH Funds $1M Research at Quest Product Development and University of Colorado for New Digitally-Controlled Endoscopes
4. Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic
5. Association of Clinical Research Organizations (ACRO) Welcomes Clinilabs and RPS as New Members
6. Melior Enters Research Collaboration with AstraZeneca
7. UC Riverside researcher develops novel method to grow human embryonic stem cells
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
9. Cryo-Cell International and EndGenitor Technologies Announce Research Collaboration
10. US Oncology Appoints Stephen Smith Vice President/General Manager Research and Personalized Science Services
11. Cyntellect to Collaborate With the Burnham Institute for Medical Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Sequenom, Inc. (NASDAQ: ... enabling healthier lives through the development of innovative products ... the United States denied its ... the claims of Sequenom,s U.S. Patent No. 6,258,540 (",540 ... criteria established by the Supreme Court,s Mayo Collaborative Services ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... ... 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona ... or pleural mesothelioma. Their findings are the subject of a new article on the ... are signposts in the blood, lung fluid or tissue of mesothelioma patients that can ...
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
Breaking Biology Technology:
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
Breaking Biology News(10 mins):